Universitat de Barcelona
2021-02-24T16:59:37Z
2021-02-24T16:59:37Z
2020-07-14
2021-02-24T16:59:37Z
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA.We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed para n-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally,
Article
Versió publicada
Anglès
Càncer de mama; Receptors d'hormones; Breast cancer; Hormone receptors
MDPI
Reproducció del document publicat a: https://doi.org/10.3390/cancers12071902
Cancers, 2020, vol. 12(7), num. 1902
https://doi.org/10.3390/cancers12071902
info:eu-repo/grantAgreement/EC/H2020/847912/EU//RESCUER
cc-by (c) Griguolo, Gaia et al., 2020
http://creativecommons.org/licenses/by/3.0/es
